<DOC>
	<DOCNO>NCT00157235</DOCNO>
	<brief_summary>The objective trial determine whether tiotropium inhalation capsule ( Spiriva , Bromuro de Tiotropio ) , compare placebo , enhance improvement exercise tolerance see patient chronic obstructive pulmonary disease ( COPD ) participate pulmonary rehabilitation .</brief_summary>
	<brief_title>Effect Tiotropium Inhalation Capsules ( Spiriva ) Exercise Tolerance COPD Patients</brief_title>
	<detailed_description>This 25-week multicenter , single country , randomise , double-blind , placebo-controlled , parallel group study compare efficacy tiotropium inhalation capsule ( Spiriva , Bromuro de Tiotropio ) patient COPD participate pulmonary rehabilitation program . Following initial screening , patient perform six minute walk test ( Visit 1 ) enter 4-week run-in period . Patients subsequently randomize tiotropium placebo inhalation capsule take daily morning next 25 week . After successfully complete 4 week study drug self-administration , patient enter period pulmonary rehabilitation . Pulmonary rehabilitation include aerobic low limb exercise 3 time weekly 8 week . After last pulmonary rehabilitation session , patient continue study medication 12 week follow-up period . Six minute walk test repeat run-in period Week 0 ( Visit 2 ) Week 4 ( Visit 3 ) , conclusion 8 week pulmonary rehabilitation ( Visit 6 ) 12 week follow-up ( Visit 9 ) . Pulmonary function test conduct prior start therapy Visit 1 Visits 2 ( week 0 ) , 3 ( week 4 ) , 6 ( week 13 ) 9 ( week 25 ) . Study Hypothesis : The null hypothesis difference increase six minute walk distance tiotropium placebo group follow 8 week pulmonary rehabilitation program . The alternative hypothesis tiotropium pulmonary rehabilitation increase six minute walk distance placebo pulmonary rehabilitation . However , two-sided test hypothesis perform 0.05 level significance . Comparison ( ) : The primary endpoint six minute walk distance visit 6 . This endpoint compare tiotropium placebo use analysis covariance model treatment , center baseline ( six-minute walk distance measure visit 2 prior dose ) covariate . Fifty-four meter determine difference six minute walk distance tiotropium ( Spiriva , Bromuro de Tiotropio ) placebo 5 % level significance least 80 % power use two-tailed t-test.. .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>COPD patient FEV1 le 60 % predict FEV1 le 70 % FVC . Patients respiratory infection six week prior Screening Visit runin period ( Visits 1 2 ) . Patients recent history ( i.e. , 6 month less ) myocardial infarction . Patients cardiac arrhythmia require drug therapy past year hospitalize heart failure within past three year . Patients symptomatic benign prostatic hypertrophy bladder neck obstruction . Patients know narrowangle glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>